Press Releases

Press Contact

Anja Heuer

Corporate Communications, Immatics N.V.

media@immatics.com

+49 89 540 415 606

Sidebar Social Links

Immatics Factsheet English

Immatics Therapeutic Approach (animation)

Always up to date: Receive posts from us and our partners via our Twitter profile.

Find out more about Immatics on LinkedIn with our News, Events & Press Releases.

English
German

Press Releases

Year

Immatics Announces Changes to its Board of Directors

Tuebingen , Germany and Houston, Texas , May 26 , 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced changes to its Board of Directors.

May 26, 2021

PDF Version

Immatics Announces First Quarter 2021 Financial Results and Business Update

Data update for ongoing ACTengine® IMA200 clinical trial series demonstrate d first anti-tumor activity in heavily pre-treated solid cancer patients during early phases of dose escalation Next ACTengine® data update for dose level s 2 and 3 on track for H2 2021 P reclinical proof-of-concept for

May 18, 2021

PDF Version

Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

Immatics ’ second TCR Bispecific s program IMA402 demonstrate s t umor cell killing in vitro and complete regression s of established tumor s in a n in vivo tumor model IMA402 targets a n Immatics - validated peptide derived from PRAME, one of the most frequent ly expressed intracellular cancer

May 11, 2021

PDF Version

Immatics Announces Full Year 2020 Financial Results and Corporate Update

Phase 1a data update from clinical ACTengine ® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients Enrollment across clinical ACTengine ® IMA200 trial series continues to scale up Cash and cash equivalents as well as other

Mar 30, 2021

PDF Version

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

Company to host conference call on Wednesday, March 17 at 8:30 am EST · First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation · Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust

Mar 17, 2021

PDF Version

IR Toolkit

Print Page
Email Alerts
RSS Feeds
Contacts